MND-SMART: the adaptive platform trial investigating potential treatments for MND
Jane Haley, PhD, MND Scotland, Glasgow, UK, shares an overview of the groundbreaking MND-SMART platform trial underway in the UK, which aims to expedite the discovery of effective treatments for motor neuron disease (MND). The charitably-funded Phase II/III trial has a unique, multi-arm, adaptive design that enables the agents being studied to change as new discoveries are made. Several agents will be studied at once, in comparison to a single placebo group, maximizing the proportion of patients receiving an active intervention. In this way, treatments that do not prove to be effective can be dropped and new ones introduced, without the time and cost limitations of launching a whole new study. The agents currently being studied are repurposed agents - memantine, amantadine, and trazodone - reducing the risks of adverse events and avoiding lengthy approval processes if proven effective. MND-SMART will run continuously for years to come, with nearly 500 patients recruited so far. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.